CoDiagnostics (CODX)
(Delayed Data from NSDQ)
$1.29 USD
-0.07 (-4.81%)
Updated Jul 15, 2024 03:58 PM ET
After-Market: $1.29 +0.01 (0.39%) 6:14 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CODX 1.29 -0.07(-4.81%)
Will CODX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CODX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CODX
Elevance Health (ELV) Beats Q1 Earnings Estimates
Icon PLC (ICLR) Q4 Earnings Surpass Estimates
CODX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
Sharecare, Inc. (SHCR) Reports Q2 Loss, Tops Revenue Estimates
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
Other News for CODX
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States
IN BRIEF: Codex Acquisitions focused on reverse takeover; loss narrows
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Co-Diagnostics (CODX)
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform